Why the study?
Does benznidazole treatment clear congenital Trypanosoma cruzi infection in a neonate?
Does benznidazole treatment clear congenital Trypanosoma cruzi infection in a neonate?
Early treatment with benznidazole successfully cleared congenital Trypanosoma cruzi infection in a neonate, highlighting the need for screening pregnant women migrating from endemic areas.
Answers are grounded in this paper and cite their sources.
Benznidazole may clear congenital T. cruzi in neonates; leaves open efficacy confirmation in prospective studies.
Here we report a documented case of congenital transmission of Trypanosoma cruzi from a Bolivian mother with chronic Chagas disease living in Spain. The serology and blood nested polymerase chain reaction (PCR) were positive for the mother, and amastigote forms were observed in histopathological study of the placenta and umbilical cord. Direct examination, culture, and nested PCR were positive in the blood of the neonate. At the age of 8 days, the neonate began treatment with 5-7.5 mg/kg/day of benznidazol, which was continued for 60 days. Direct examination, blood culture, and nested PCR were negative to T. cruzi 20 days after the start of treatment and remained negative 4 and 7 months thereafter. Serological tests were negative at 4 months. To detect congenital infection and initiate early treatment of infected newborns, protocols are required to detect Chagas disease in pregnant women who migrate from endemic to non-endemic areas.
No takes yet. Share an insight, caveat, or question.
Riera et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: